Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.
- Advancement of key partnerships with Genentech, Medicxi, and Radiopharm Theranostics
- Preclinical radiopharmaceutical program nearing clinical trial initiation
- Record online sales month for Viraleze™ with 70% year-to-date growth
- Received USD $5.5 million upfront payment from Genentech
- Cash balance of $18.2 million supports ongoing R&D and marketing initiatives
Strategic Partnerships Drive Momentum
Starpharma has made significant strides in the second quarter of fiscal year 2026, focusing on executing its priority partnerships with industry leaders such as Genentech, Medicxi, and Radiopharm Theranostics. The company received a substantial upfront payment of USD $5.5 million from Genentech, reflecting confidence in Starpharma’s dendrimer technology and its potential to enhance oncology treatments. Collaborative efforts with Radiopharm Theranostics are progressing well, with the first phase of their radiopharmaceutical development nearing completion and potential milestone payments on the horizon.
These partnerships not only validate Starpharma’s proprietary DEP® platform but also open pathways for further licensing and development opportunities. The Star Navigator program, designed to facilitate early-stage collaborations, continues to attract interest, positioning Starpharma as a sought-after partner in the biotech sector.
Advancing Internal Pipeline and Clinical Readiness
Internally, Starpharma is advancing its preclinical DEP® HER2 radiopharmaceutical program with the goal of commencing first-in-patient trials within the year. The company has made substantial progress in preclinical pharmacology and toxicology studies, and regulatory preparations are well underway, including clinical site selection. This progress underscores Starpharma’s commitment to translating its innovative dendrimer technology into tangible clinical outcomes.
Alongside this, the company continues to refine its pipeline, exploring novel therapeutic modalities that leverage the unique properties of dendrimers. This strategic focus aims to identify new commercial opportunities and enhance the versatility of their technology platform.
Commercial Growth Fueled by Viraleze™
On the commercial front, Starpharma achieved its highest-ever online sales month for Viraleze™ in November, with year-to-date online sales up 70% compared to the previous corresponding period. This growth is attributed to intensified marketing efforts, including targeted digital campaigns on platforms like Meta and TikTok, as well as innovative initiatives such as an in-flight magazine campaign during the Northern Hemisphere’s cold and flu season.
Further expanding its market reach, Starpharma secured an exclusive distribution agreement with Adelvas LLC for Viraleze™ across key Eurasian markets, including Russia and Kazakhstan. The company also continues to support its global partners for both Viraleze™ and VivaGel® BV, with encouraging early commercial activity in the Middle East and successful regulatory registrations in the UK.
Financial Position and Outlook
Starpharma’s financial health remains robust, with a cash balance of $18.2 million at the end of December 2025. Operating cash inflows were positive, supported by customer receipts and milestone payments, while research and development and staffing costs were managed prudently. The company did not raise new equity or debt during the quarter, reflecting confidence in its current funding runway.
CEO Cheryl Maley highlighted the company’s clear strategic priorities for 2026 – advancing clinical programs, securing new partnerships and licensing deals, and driving revenue growth through product sales. The recent recognition as a Great Place to Work further signals a strong internal culture supporting these ambitions.
Bottom Line?
With partnerships gaining traction and commercial momentum building, Starpharma’s next milestones will be critical in validating its technology’s market potential.
Questions in the middle?
- When will the DEP® HER2 radiopharmaceutical program officially enter clinical trials?
- How soon might milestone payments from Radiopharm Theranostics materialize?
- What new partnerships could emerge from the Star Navigator program in 2026?